Sparse Batch Number Reporting for Biologicals in FDA's Adverse Event Reporting System (AERS)

被引：0

作者：

Vermeer, N. S. ^{[1
,2
]}

Straus, S. M. ^{[2
,3
]}

Teeuwisse, A. K. Mantel ^{[1
]}

Egberts, T. C. ^{[1
]}

Leufkens, H. G. ^{[1
,2
]}

De Bruin, M. L. ^{[1
,2
]}

机构：

[1] Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, UIPS, Utrecht, Netherlands

[2] Med Evaluat Board, The Hague, Netherlands

[3] Erasmus MC, Dept Med Informat, Rotterdam, Netherlands

来源：

DRUG SAFETY | 2011年 / 34卷 / 10期

关键词：

BIOPHARMACEUTICALS;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

引用

下载

页码：1002 / 1002

页数：1

共 50 条

[21] AERscope: A Streamlined Method To Describe FDA Adverse Event Reporting System (AERS) Data Using a Novel SAS/IntrNet Application
Guo, Ted
Jones, Chris
Zhao, Enxu
Gelperin, Kate
Swartz, Lynette
Du, Tony
Rothstein, Adrienne
Swann, Joslyn
Hammad, Tarek A.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S335 - S335
[22] Adverse Event Reporting Patterns of Newly Approved Drugs in the USA in 2006: An Analysis of FDA Adverse Event Reporting System Data
Chhabra, Pankdeep
Chen, Xing
Weiss, Sheila R.
DRUG SAFETY, 2013, 36 (11) : 1117 - 1123
[23] Adverse Event Profiles of 5-Fluorouracil and Capecitabine: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
Kadoyama, Kaori
Miki, Ikuya
Tamura, Takao
Brown, J. B.
Sakaeda, Toshiyuki
Okuno, Yasushi
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2012, 9 (01): : 33 - 39
[24] A Review of Dental Adverse Events Using the FDA Adverse Event Reporting System
Altman, Keith
Budny, Renata
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 400 - 400
[25] Differences in Anaphylaxis Reporting Among Cephalosporins: Analysis of the FDA Adverse Event Reporting System Database
Shah, Divya
Stone, Cosby
Rukasin, Christine
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB77 - AB77
[26] ADVERSE EVENTS ASSOCIATED WITH THE USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI'S) ANTIDEPRESSANT MEDICATIONS AMONG CHILDREN: A REVIEW OF THE FDA ADVERSE EVENT REPORTING SYSTEM (AERS)
Chen, H.
VALUE IN HEALTH, 2009, 12 (07) : A290 - A290
[27] Comparison of adverse reaction reports for rivastigmine and donepezil using the FDA's adverse event reporting system
Rizzo, J
Chang, SB
Ofman, J
NEUROBIOLOGY OF AGING, 2002, 23 (01) : S116 - S116
[28] Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system
Raisch, Dennis W.
Rafi, John A.
Chen, Cheng
Bennett, Charles L.
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (08) : 1003 - 1011
[29] Comparison of adverse reaction reports for rivastigmine, and donepezil using the FDA's Adverse Event Reporting System
Rizzo, JA
Chang, SB
Cohen, A
ANNALS OF NEUROLOGY, 2001, 50 (03) : S76 - S76
[30] Data Mining of the Public Version of the FDA Adverse Event Reporting System
Sakaeda, Toshiyuki
Tamon, Akiko
Kadoyama, Kaori
Okuno, Yasushi
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2013, 10 (07): : 796 - 803

← 1 2 3 4 5 →